What Clearmind Medicine does

Clearmind Medicine is a clinical-stage pharmaceutical biotech developing non-hallucinogenic, psychedelic-derived therapeutics based on its proprietary molecule MEAI (5-methoxy-2-aminoindane). The company's lead candidate, CMND-100, is an oral drug in FDA-regulated Phase I/IIa trials for Alcohol Use Disorder (AUD), with dosing completed across all 24 participants in 4 cohorts at Yale School of Medicine, Johns Hopkins, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center. The company's mechanism targets 5-HT1A receptors to produce an alcohol-like euphoric experience while signaling satiety, positioning it as a 'binge-mitigating agent' that could address AUD, binge eating, gambling, and other impulse-control disorders.

Clearmind is pursuing an expanding indication strategy through preclinical programs combining MEAI with tirzepatide (with Yissum/Hebrew University) for obesity and metabolic dysfunction-associated steatotic liver disease, and with Palmitoylethanolamide (with NeuroThera Labs/SciSparc) for binge behavior and metabolic indications. The intellectual property portfolio comprises 32 granted patents across 19 patent families spanning the US, Europe, India, China, Hong Kong, Japan, South Korea, Mexico, and Australia, with additional filings in depression and PTSD. A February 2026 development agreement with Polyrizon extends the product surface into intranasal delivery.

The company is pre-revenue and headquartered in Vancouver, Canada with operational offices in Tel Aviv, Israel. It is publicly listed on NASDAQ (CMND), the Frankfurt Stock Exchange (CWY0), and the Canadian Securities Exchange (CMND), employs 11-50 staff, and is led by CEO Dr. Adi Zuloff-Shani. The revenue model is contingent on future FDA approval of CMND-100, after which Clearmind intends to commercialize via prescription drug sales targeting patients with AUD and other indications, and to monetize its patent estate through licensing agreements with larger pharmaceutical companies. Cumulative funding raised to date includes approximately $8.15M in equity offerings plus up to $10M in committed convertible-note financing, with market capitalization of roughly $2.5M as of May 2026 following two reverse stock splits.

Name

Clearmind Medicine

Legal name

Clearmind Medicine Inc.

Website

https://clearmindmedicine.com

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Clearmind Medicine is a clinical-stage biotech developing non-hallucinogenic, MEAI-based psychedelic therapeutics, led by CMND-100 for Alcohol Use Disorder in FDA Phase I/IIa trials, with pipeline expansion into obesity, depression, PTSD, and binge behavior disorders.

Ownership category

akta.pro rank

Product category

Psychedelic Pharmaceuticals / Biotech Therapeutics

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Psychedelic therapeutics
• Alcohol use disorder treatment
• Binge behavior regulation
• Neuroplastogen drug development
• Mental health pharmaceuticals

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Pre-revenue clinical-stage biotech. Once CMND-100 receives regulatory approval (FDA), the company intends to commercialize its proprietary drug candidates as regulated medicines. Revenue would come from prescription drug sales targeting patients with Alcohol Use Disorder and other indications.
2. Licensing Royalties: The company may pursue licensing agreements with larger pharmaceutical companies for the development and commercialization of its proprietary compounds and patent portfolio in various jurisdictions and therapeutic indications.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

Core offering

Clearmind Medicine is a clinical-stage biotech developing proprietary non-hallucinogenic psychedelic-derived therapeutics based on its novel molecule MEAI (5-methoxy-2-aminoindane). Its lead candidate CMND-100 is an oral drug for Alcohol Use Disorder currently in FDA-regulated Phase I/IIa clinical trials. The company also develops MEAI-based combination therapies for obesity, metabolic disorders, depression, PTSD, and binge behavior disorders.

Product overview

Clearmind Medicine is a clinical-stage neuroplastogens pharmaceutical biotech company developing non-hallucinogenic, second-generation psychedelic-derived therapeutics. The company's primary product portfolio centers on CMND-100, a proprietary oral drug candidate based on the MEAI (5-methoxy-2-aminoindane) molecule, which is being developed primarily for Alcohol Use Disorder (AUD) treatment. The MEAI molecule acts as a 'binge-mitigating agent' that produces alcohol-like euphoria while signaling the brain that it is satisfied, reducing the desire to consume alcohol. CMND-100 is currently undergoing Phase I/IIa FDA-regulated clinical trials at leading institutions. The company is also exploring additional therapeutic applications of MEAI including depression, obesity/metabolic disorders, PTSD, and cocaine addiction. Clearmind's intellectual property portfolio consists of 19 patent families with 32 granted patents across multiple jurisdictions worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

• CMND-100 Proprietary non-hallucinogenic MEAI-based oral drug candidate for treating Alcohol Use Disorder (AUD). Currently in Phase I/IIa FDA-regulated clinical trials at leading institutions including Yale School of Medicine, Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center. Demonstrated strong safety profile with no serious adverse events reported across all 24 participants in Part A.
• MEAI (5-methoxy-2-aminoindane) Proprietary psychoactive aminoindane molecule that exerts a euphoric alcohol-like experience and reduces desire to consume alcoholic beverages. Acts on neural pathways including 5-HT1A to decrease impulsivity. Active ingredient in CMND-100, being developed for multiple indications including AUD, depression, obesity, and binge behaviors.

Quantifiable outcome

• Phase I/IIa trial: All 24 participants across Cohorts 1-4 completed treatment with strong safety profile, no serious adverse events reported
• +3 more outcomes

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Seven partnerships are on record, tiered core.

• Yissum Research Development Company of Hebrew University of JerusalemcoreStrategic or Co-development Partner · 18 May 202612-month preclinical research agreement evaluating MEAI (CMND-100) in combination with tirzepatide and as maintenance therapy following tirzepatide treatment in diet-induced obese mice. Study conducted by Professor Joseph Tam's team at Hebrew University. Builds on prior research showing MEAI achieved approximately 15-20% body weight reduction through increased energy expenditure while preserving lean mass.
• NeuroThera Labs Inc. (Subsidiary of SciSparc Ltd.)coreStrategic or Co-development Partner · 10 March 2026Collaboration on combination therapy of MEAI with Palmitoylethanolamide (PEA) targeting obesity, metabolic dysfunction-associated steatotic liver disease (MASLD), and binge behavior disorders. Collaboration has resulted in 13 patent families across multiple jurisdictions. MEAI provides neuroplastic properties while PEA offers anti-inflammatory and neuroprotective benefits.
• Polyrizon Ltd.coreTechnology or Integration · 6 February 2026Development agreement to create an intranasal formulation of MEAI using Polyrizon's proprietary intranasal hydrogel technology. The partnership aims to improve bioavailability through enhanced nasal residence time and targeted delivery for CNS-targeted compounds. Classified as a related party transaction under Canadian securities regulations.
• Tel Aviv Sourasky Medical Center (TASMC)coreStrategic or Co-development PartnerClinical trial site for Phase I/IIa trial of CMND-100 for Alcohol Use Disorder. Study led by Dr. David Zeltser, Director of Emergency Medicine Department. One of the leading clinical sites in Israel participating in the multinational trial.
• Hadassah-University Medical CentercoreStrategic or Co-development PartnerClinical trial site for Phase I/IIa trial of CMND-100 for Alcohol Use Disorder. Led by Prof. Yossi Karko, Director of Center for Clinical Research, and Prof. Joseph Caraco, Director of Clinical Pharmacology Unit. One of the premier research institutions in Israel.
• Yale School of MedicinecoreStrategic or Co-development PartnerLeading U.S. clinical trial site for Phase I/IIa trial of CMND-100. Department of Psychiatry involvement in the FDA-regulated multicenter, randomized, double-blind, placebo-controlled study.
• Johns Hopkins University School of MedicinecoreStrategic or Co-development PartnerLeading U.S. clinical trial site for Phase I/IIa trial of CMND-100. Johns Hopkins Medicine Institutional Review Board approved advancement to Parts B and C of the trial. Key site for safety and tolerability evaluation.

Scale indicators8 records

Recent moves7 records

Expansion highlights7 records

Broad incumbents

• Tonix Pharmaceuticals: Commercial and clinical-stage CNS-focused biopharmaceutical company with a broader neurology and psychiatry portfolio (e.g., fibromyalgia, migraine). Overlaps with Clearmind's CNS specialty pharmaceutical focus but operates across a wider set of indications.
• Axsome Therapeutics: Commercial-stage CNS biopharmaceutical company with FDA-approved Auvelity for major depressive disorder and others for migraine. Comparable as a publicly-traded CNS specialty pharma pursuing novel mechanisms in psychiatry.
• Sage Therapeutics: Established CNS biopharmaceutical company with FDA-approved Zurzuvae for postpartum depression and a pipeline targeting depression and neurological disorders. A broader incumbent in the CNS specialty pharmaceutical category where Clearmind also operates.

Direct peers

• Cybin: Clinical-stage psychedelic therapeutics company developing deuterated psilocybin analog CYB003 for depression and other mental health conditions. Comparable in size, stage, and psychedelic CNS focus.
• Compass Pathways: Late-stage psychedelic biotech developing psilocybin therapy for treatment-resistant depression. Comparable to Clearmind as a publicly-traded, FDA-regulated psychedelic therapeutics company pursuing CNS indications with proprietary novel molecules.
• GH Research: Clinical-stage company developing mebufotenin and other psychedelic-derived candidates for treatment-resistant depression. Comparable to Clearmind as a small-cap, FDA-regulated psychedelic therapeutics developer focused on CNS indications.
• atai Life Sciences: Clinical-stage biopharmaceutical platform developing psychedelic and non-psychedelic therapeutics for mental health, including depression and addiction. Closely comparable to Clearmind in psychedelic-derived CNS pipeline strategy.
• MindMed: Clinical-stage psychedelic medicine biotech developing candidates for anxiety, ADHD, and substance use disorders. Directly comparable to Clearmind as a public, CNS-focused psychedelic-derived therapeutics developer with overlapping addiction indications.

Emerging players

• NeuroThera Labs (SciSparc): Specialty pharmaceutical company developing cannabinoid-based therapies for CNS indications, including a collaboration with Clearmind on MEAI+PEA combinations. Directly involved as a partner and represents a peer in CNS combination therapeutics.
• Bionomics Limited: Clinical-stage CNS biopharmaceutical company developing BNC210 for anxiety and PTSD. Comparable as a small-cap CNS-focused emerging player targeting overlapping mental health indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/ClearmindCMND
• YouTubeyoutube.com/channel/UCg_JDmUZSqstavsbd3zYmmg
• Facebookfacebook.com/ClearmindMedicine
• LinkedInlinkedin.com/company/clearmind-medicine
• Instagraminstagram.com/clearmindmed

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds4 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Clearmind Medicine